TY  - CHAP
M1  - Book, Section
TI  - Gastrointestinal Stromal Tumors
A1  - Hong, Nicole J. Look
A1  - Raut, Chandrajit P.
A2  - Zinner, Michael J.
A2  - Ashley, Stanley W.
A2  - Hines, O. Joe
PY  - 2019
T2  - Maingot's Abdominal Operations, 13e
AB  - Gastrointestinal  stromal  tumors  (GISTs)  are  rare  neoplasms.  Although  they  represent  only  0.1%  to  3%  of  all  gastrointestinal  malignancies,1–4  they  account  for  80%  of  gastrointestinal  mesenchymal  neoplasms.5  Approximately  5000  to  6000  new  cases  are  diagnosed  per  year  in  the  United  States,  for  an  annual  incidence  of  14.5  per  million  and  prevalence  of  129  per  million.6  In  the  last  15  years,  the  understanding  and  treatment  of  GIST  has  witnessed  remarkable  advances  due  to  two  key  developments:  (1)  the  identification  of  constitutively  active  signals  (oncogenic  mutation  of  the  c-KIT  and  platelet-derived  growth  factor  alpha  [PDGFRA]  gene-encoding  receptor  tyrosine  kinases)  and  (2)  the  development  of  therapeutic  agents  that  suppress  tumor  growth  by  specifically  targeting  and  inhibiting  these  signals.  These  developments  in  the  management  of  GIST  illustrate  the  principle  of  translational  therapeutics  in  oncology,  confirming  that  specific  inhibition  of  tumor-associated  receptor  tyrosine  kinase  activity  is  an  effective  cancer  treatment.  The  advent  of  effective  targeted  medical  therapy  for  GIST  has  increased  the  complexity  of  management  and  opened  new  dialogues  regarding  the  need  for  integrated  multimodality  therapy.  This  chapter  reviews  the  biology,  treatment,  and  emerging  clinical  challenges  of  these  mesenchymal  neoplasms.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesssurgery.mhmedical.com/content.aspx?aid=1160040797
ER  -